Compare EPR Properties (EPR) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs Medpace Holdings Inc — how do they compare? EPR Properties trades at $54.85 (market cap $4.17B), while Medpace Holdings Inc trades at $615.17 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 4× EPR Properties's market cap, and EPR Properties pays a 6.84% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold EPR Properties for 45 Days and Medpace Holdings Inc for 14 Days on average.
| EPR | MEDP | |
|---|---|---|
Market Cap | $4.17B | $16.82B |
Volume | 992,716 | 223,093 |
Sector | Real Estate | Health |
52-Week High | $64.32 | $630.19 |
52-Week Low | $48.71 | $393.42 |
Typical Hold Time | 45 Days | 14 Days |
Enterprise Value | $7.68B | $16.44B |
Dividend Yield | 6.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $54.49, up 0.76% today, with a bearish technical signal but oversold oscillators suggesting potential reversal. The REIT shows strong profitability with a 37.66% net income margin and a 6.5% dividend yield, though earnings have been mixed with a recent miss in Q1 2026. Analysts maintain a consensus Buy rating with a $65.50 price target, implying significant upside from current levels.
The outlook is cautiously optimistic given the high dividend yield and discounted valuation, but risks include exposure to interest rate sensitivity and tenant performance in its experiential real estate portfolio. Near-term catalysts include the Q3 2026 earnings release on October 28, 2026, which could validate the company's growth trajectory amid a challenging macro environment.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
